Literature DB >> 3089800

Changes in thyroid function tests induced by 2 month carbamazepine treatment in L-thyroxine-substituted hypothyroid children.

F De Luca, T Arrigo, E Pandullo, M F Siracusano, S Benvenga, F Trimarchi.   

Abstract

In five L-thyroxine-substituted hypothyroid children with partial epilepsy serum total thyroxine (T4) and free T4 (FT4) significantly (P less than 0.01) decreased following 2 months of carbamazepine (CBZ) administration (20 mg/kg per BW per day) from mean (+/- SD) values of 12.7 +/- 1.1 micrograms/dl and 15.5 +/- 1.8 pg/ml to mean values of 7.5 +/- 2.3 and 10.1 +/- 1.7, respectively. In all but one patient important changes in both serum total and free triiodothyronine (T3, FT3) were not observed; consequently T3:T4 and FT3:FT4 ratios significantly (P less than 0.05) increased in the whole series. Three subjects had post-treatment serum TSH that rose to hypothyroid levels parallel to a T4 decrease. The negligible thyroid hormone secretion and the unmodified T3-uptake (T3U) or T4-binding globulin (TBG) exclude direct effects of CBZ on thyroid gland and on carrier serum proteins, respectively. The findings observed, instead, might be due to accelerated T4 metabolic clearance together with augmented T4 to T3 conversion rate, as previously demonstrated for diphenylhydantoin. The sharp reduction in T4 and FT3 concentrations is the peripheral display of this event, which is associated with a decompensation of the metabolic status, as indicated by serum TSH enhancement. In all cases a supplement of L-thyroxine by itself was able to restore euthyroid TSH serum concentrations, suggesting that hypothyroidism in patients with partial epilepsy to whom CBZ had been administered requires a higher L-T4 substitutive regimen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3089800     DOI: 10.1007/bf00441860

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  17 in total

1.  Thyroid hormone levels and protein binding in patients on long-term diphenylhydantoin treatment.

Authors:  P Heyma; R G Larkins; D Perry-Keene; C T Peter; D Ross; J G Sloman
Journal:  Clin Endocrinol (Oxf)       Date:  1977-05       Impact factor: 3.478

2.  Effect of 5,5'-diphenylhydantoin on the metabolism of L-thyroxine-131-I in the rat.

Authors:  D M Mendoza; E V Flock; C A Owen; J Paris
Journal:  Endocrinology       Date:  1966-07       Impact factor: 4.736

3.  The effect of diphenylhydantoin on thyroxine metabolism in man.

Authors:  P R Larsen; A J Atkinson; H N Wellman; R E Goldsmith
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

4.  Pharmacological influences on T4 to T3 conversion in rat liver.

Authors:  M Hüfner; M Knöpfle
Journal:  Clin Chim Acta       Date:  1976-11-01       Impact factor: 3.786

5.  Anticonvulsants and thyroid function.

Authors:  P P Yeo; D Bates; J G Howe; W A Ratcliffe; C W Schardt; A Heath; D C Evered
Journal:  Br Med J       Date:  1978-06-17

6.  Augmentation of thyrotropin responses to thyrotropin-releasing hormone following small decreases in serum thyroid hormone concentrations.

Authors:  M Saberi; R D Utiger
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

7.  Thyroid function tests in patients on long-term treatment with various anticonvulsant drugs.

Authors:  K Liewendahl; H Majuri; T Helenius
Journal:  Clin Endocrinol (Oxf)       Date:  1978-03       Impact factor: 3.478

8.  Increased thyroxine turnover and thyroidal function after stimulation of hepatocellular binding of thyroxine by phenobarbital.

Authors:  J H Oppenheimer; G Bernstein; M I Surks
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

9.  Hypothyroidism induced by anti-epileptic therapy.

Authors:  S Aanderud; R E Strandjord
Journal:  Acta Neurol Scand       Date:  1980-05       Impact factor: 3.209

10.  Hyperresponse to thyrotropin-releasing hormone accompanying small decreases in serum thyroid hormone concentrations.

Authors:  A G Vagenakis; B Rapoport; F Azizi; G I Portnay; L E Braverman; S H Ingbar
Journal:  J Clin Invest       Date:  1974-10       Impact factor: 14.808

View more
  8 in total

1.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

Review 2.  Hypothyroidism in the elderly: pathophysiology, diagnosis and treatment.

Authors:  Peter Laurberg; Stig Andersen; Inge Bülow Pedersen; Allan Carlé
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 3.  Risk-benefit assessment of carbamazepine in children.

Authors:  M N Seetharam; J M Pellock
Journal:  Drug Saf       Date:  1991 Mar-Apr       Impact factor: 5.606

Review 4.  Drug-induced thyroid disorders.

Authors:  N J Gittoes; J A Franklyn
Journal:  Drug Saf       Date:  1995-07       Impact factor: 5.606

Review 5.  A Review of the Pharmacokinetics of Levothyroxine for the Treatment of Hypothyroidism.

Authors:  Philippe Colucci; Corinne Seng Yue; Murray Ducharme; Salvatore Benvenga
Journal:  Eur Endocrinol       Date:  2013-03-15

Review 6.  Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy.

Authors:  Francesco Torino; Salvatore Maria Corsello; Raffaele Longo; Agnese Barnabei; Giampietro Gasparini
Journal:  Nat Rev Clin Oncol       Date:  2009-04       Impact factor: 66.675

Review 7.  Review of Heterotopic Thyroid Autotransplantation.

Authors:  Mahmoud Sakr; Ahmed Mahmoud
Journal:  Clin Exp Otorhinolaryngol       Date:  2017-05-24       Impact factor: 3.372

Review 8.  L-T4 Therapy in the Presence of Pharmacological Interferents.

Authors:  Salvatore Benvenga
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-22       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.